

Thursday 31st October 2019

12:00	Arrival	
12:30	<p>Welcome (Lecture Hall)</p> <p>Introduction Evolution of HSCT to evidence-based therapy</p>	<p>Renate Arnold, Tobias Alexander, John Snowden, Helen Jessop (on behalf of the EBMT Nurses Group)</p> <p>John Snowden (Sheffield)</p>
13:00-14:30	<p>Scientific Session: Immunologic mechanisms and the microbiome (Lecture Hall) (20 minutes + 10 minutes discussion)</p> <p>Autoreactive memory drives persistent inflammation in AD</p> <p>Reset of autoimmunity into self-tolerant state with HSCT</p> <p>Interaction of microbiota and HSCT, and how this may influence immune responses in AD</p>	<p>Gerd Burmester, Britta Siegmund</p> <p>Andreas Radbruch (Berlin)</p> <p>Paolo Muraro (London)</p> <p>Ernst Holler (Regensburg)</p>
13:00-14:30	<p>Nurses Parallel Session (Gallery) (10 minutes + 5 minutes discussion)</p> <p>Information and supportive care management in</p> <p>a) MS b) Rheumatic diseases c) Crohn's disease d) Patients going and returning from overseas e) HSCT from a MS patient perspective</p>	<p>Helen Jessop</p> <p>Claudia Boglione (Florence) Tina Hansmann and Birgit Jung (Tübingen) Ariadna Domenec (Barcelona) Helen Jessop (Sheffield) Susanne Bärlein (Germany)</p>
14:30-16:00	<p>Conditioning regimen in HSCT for autoimmune diseases: how can we adapt it to improve outcomes? (Lecture Hall) (20 minutes + 5 minutes discussion)</p> <p>Toward a cure for severe scleroderma: HSCT regimens and outcome measurements</p> <p>Adapting transplant technique to disease-specific requirements in autologous HSCT: Modifying the Non-myeloablative approach</p> <p>Post-transplant Cyclophosphamide: a means of enhancing tolerance? (15 min + 5 min discussion)</p> <p>Fertility and gonadal following HSCT for autoimmune diseases (15 min + 5 min discussion)</p>	<p>Riccardo Saccardi, Tobias Alexander</p> <p>Keith Sullivan (Durham)</p> <p>Richard Burt (Chicago)</p> <p>Raffaella Greco (Milan)</p> <p>Nina Salooja (London)</p>
16:00-16:30	Tea/Coffee	
16:30-18:00	<p>Cell therapy (Lecture Hall) (20 minutes + 10 minutes discussion)</p> <p>CAR T-cells: Challenges and opportunities in AD</p> <p>CAR T-cells: From translational science to an approved therapy</p> <p>Adoptive T-cell transfer for infection prophylaxis and relapse prevention</p>	<p>John Snowden, Renate Arnold</p> <p>Stefan Miltenyi (Bergisch-Gladbach, Miltenyi Biotec)</p> <p>Alexander Shimabukuro-Vornhagen (Köln)</p> <p>Hermann Einsele (Würzburg)</p>
19:00	Dinner	

Friday 1st November 2019

08:30-10:00	<p>State-of-the-art for autologous HSCT in autoimmune diseases (Lecture Hall) (15 minutes + 5 minutes discussion)</p> <p>HSCT in Systemic Sclerosis HSCT in Multiple Sclerosis HSCT in Crohn's Disease HSCT for IDDM and other rare AD indications</p>	<p>John Snowden, Renate Arnold</p> <p>Dominique Farge (Paris) Riccardo Saccardi (Firenze) Montserrat Rovira (Barcelona) Maria Carolina Oliveira (Ribeirão Preto)</p>
10:00-10:30	<p>Tea/Coffee</p>	
10:30-12:00	<p>Parallel Session I: Neurology (Lecture Hall) (10 minutes + 10 minutes discussion)</p> <p>Conventional treatment of refractory MS Moscow experience of HSCT in MS EBMT Guidelines for HSCT in MS and other neurological diseases Prospective transplantation studies in MS</p>	<p>Riccardo Saccardi, Joachim Burman</p> <p>Christoph Heesen (Hamburg) DA Federenko (Moscow) Basil Sharrack (Sheffield)</p> <p>Lars Bø for RAM-MS trial (Bergen)</p>
10:30-12:00	<p>Parallel Session II: Rheumatology (Terrace Room) (10 minutes + 10 minutes discussion)</p> <p>HSCT in SLE and other rheumatic diseases Patient selection in SSc Maintenance therapy in SSc Immunological studies and biomarkers</p>	<p>Falk Hiepe, Joerg Henes</p> <p>Tobias Alexander (Berlin) Jeska de Vries-Bouwstra (Leiden) Nicoletta del Papa (Milano) Keith Sullivan (Duke)</p>
10:30-12:00	<p>Parallel Session III: Gastroenterology (Library) (10 minutes + 10 minutes discussion)</p> <p>Update on conventional approaches to Crohn's disease and ulcerative colitis: where may HSCT have a role? ASTICLight - trial update Experience of allogeneic HSCT in CD Mucosal microRNA profiles and response to HSCT</p>	<p>Chris Hawkey, Majid Kazmi</p> <p>Chris Hawkey (Nottingham)</p> <p>J Snowden (Sheffield) & G Pockley (Nottingham) Richard Burt (Chicago) Amy Lewis (London)</p>
12:00-13:00	<p>Lunch Symposium (Mallinckrodt)</p> <p>Extracorporeal Photopheresis (ECP) – Potential Mode of Action and role in Autoimmune Diseases</p>	<p>Tobias Alexander</p> <p>Hans-Jochem Kolb (Munich)</p>
13:00-14:30	<p>'Cross-fertilisations' Session (Lecture Hall) (15 minutes + 5 minutes discussion)</p> <p>Chemotherapy and ATG: real life 'exposure' versus 'dose'. Could it affect outcomes of HSCT in autoimmune diseases? HSCT for paediatric ADs, including monogenic autoimmune and autoinflammatory diseases Allogeneic HSCT for adrenoleukodystrophy; what lessons can we learn for HSCT in autoimmune diseases Late effects of HSCT in autoimmune diseases</p> <p>Closing remarks</p>	<p>John Snowden, Lars Bullinger</p> <p>Jürgen Kuball (Utrecht)</p> <p>Arjan Lankester (Leiden, IEWP Chair)</p> <p>Joern-Sven Kuehl (Leipzig)</p> <p>Kirill Kirgizov (Moscow)</p> <p>Falk Hiepe, John Snowden, Helen Jessop (on behalf of the EBMT Nurses Group)</p>
14:30-16:00	<p>Business Meeting (Gallery)</p>	